Related Experiment Videos
Polycyclic aromatic hydrocarbon-DNA adducts and the CYP1A1 restriction fragment length polymorphism
P G Shields1, H Sugimura, N E Caporaso
1Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, MD 20892.
Environmental Health Perspectives
|November 1, 1992
Summary
Investigating human cancer risk involves studying carcinogen metabolism and DNA adducts. Genetic testing for metabolic capacity, like CYP1A1 variations, may indicate cancer risk, but findings vary across populations.
Area of Science:
- Environmental Health
- Genetics
- Molecular Toxicology
Background:
- Human cancer risk assessment integrates genetic factors like carcinogen metabolism and DNA adduct formation.
- Interindividual variability in metabolism influences DNA adduct levels, making them a potential measure of biologically effective dose.
- Chemically specific assays for DNA adducts are advancing, with improvements in quantifying polycyclic aromatic hydrocarbon DNA adducts using a modified 32P-postlabeling assay.
Purpose of the Study:
- To explore the relationship between genetic variations in carcinogen metabolism and cancer risk.
- To evaluate the utility of DNA adducts as a biomarker for carcinogen exposure and genotoxic effects.
- To investigate the association of CYP1A1 genetic polymorphisms with lung cancer risk in different populations.
Main Methods:
- Utilizing a modified 32P-postlabeling assay for enhanced quantification of polycyclic aromatic hydrocarbon DNA adducts.
- Conducting genetic testing to assess metabolic capacity for carcinogen activation.
- Performing a U.S. lung cancer case-control study to examine associations between genetic factors and disease risk.
Main Results:
- A restriction fragment length polymorphism in CYP1A1, a key enzyme in activating carcinogenic polycyclic aromatic hydrocarbons, was associated with lung cancer risk in a Japanese population.
- In a U.S. lung cancer case-control study subset, no association was found between CYP1A1 genetic variations and lung cancer risk.
- DNA adducts reflect recent exposure, while genetic testing indicates long-term metabolic capacity for genotoxic effects.
Conclusions:
- Genetic testing for metabolic capacity, such as CYP1A1 polymorphisms, may serve as an integrated risk factor for cancer.
- The association between CYP1A1 polymorphisms and lung cancer risk may be population-specific.
- Further research is needed to fully understand the interplay of genetic predisposition, environmental exposures, and cancer development.